Desipramine induces apoptotic cell death through nonmitochondrial and mitochondrial pathways in different types of human colon carcinoma cells

Pharmacology

Volumn 81, Issue 2, 2008, Pages 164-172

  Arimochi, Hideki ^a   Morita, Kyoji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Apoptotic damage; Desipramine; HCT116 cells; HT29 cells; Human colon cancer cells; Mitochondrial pathways; Nonmitochondrial pathways

Indexed keywords

DESIPRAMINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DEATH; CELL STRAIN HCT116; CELL STRAIN HT29; CELL VIABILITY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HT29 CELLS; HUMANS; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 38749102342     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111144     Document Type: Article

References (45)

1. Cotterchio M, Kreiger N, Darlington G, Steingart A: Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151:951-957.
2. Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF: The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002;86:92-97.
3. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S: Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 2000;11:839-845.
4. Dalton SO, Johansen C, Mellemkjaer L, Sorensen HT, McLaughlin JK, Olsen J, Olsen JH: Antidepressant medications and risk for cancer. Epidemiology 2000;11:171-176.
5. Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS: Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 2002;13:35-45.
6. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J: Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001;54:728-734.
7. Weiss SR, McFarland BH, Burkhart GA, Ho PT: Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 1998;63:594-599.
8. Abdul M, Logothetis CJ, Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995;154:247-250.
9. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 1992;52:6931-6935.
10. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS: Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992;52:3796-3800.
11. Freire-Garabal M, Nunez MJ, Pereiro D, Riveiro P, Losada C, Fernandez-Rial JC, Garcia-Iglesias E, Prizmic J, Mayan JM, Rey-Mendez M: Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 1998;63:PL31-PL38.
12. 1-induced hepatic preneoplastic foci. Carcinogenesis 1999;20:1793-1799.
13. Sternbach H: Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry 2003;64:1153-1162.
14. Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, Wohlrab W, Heinemann SH: Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002;188:137-149.
15. Koch JM, Kell S, Aldenhoff JB: Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell viability. J Psychiatr Res 2003;37:53-59.
16. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J: Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003;101:3212-3219.
17. Slamon ND, Pentreath VW: A comparison of the acute and chronic effects of antidepressants in cultured C6 and 1321N1 cells. ATLA 1998;26:303-319.
18. Slamon ND, Pentreath VW: Antioxidant defense against antidepressants in C6 and 1321N1 cells. Chem Biol Interact 2000;127:181-199.
19. Slamon ND, Ward TH, Butler J, Pentreath VW: Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay. Arch Toxicol 2001;75:243-250.
20. Xia Z, Bergstrand A, DePierre JW, Nassberger L: The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol 1999;13:338-347.
21. Xia Z, DePierre JW, Nassberger L: Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J Biochem Mol Toxicol 1998;12:115-123.
22. Li YF, Liu YQ, Huang WC, Luo ZP: Cytoprotective effect is one of common action pathways for antidepressants. Acta Pharmacol Sin 2003;24:996-1000.
23. Li YF, Luo ZP: Desipramine antagonized corticosterone-induced apoptosis in cultured PC12 cells. Acta Pharmacol Sin 2002;23:311-314.
24. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ: Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 2003;3:169-184.
25. Iishi H, Tatsuta M, Baba M, Taniguchi H: Enhancement by the tricyclic antidepressant, desipramine of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis 1993;14:1837-1840.
26. Tutton PJ, Barkla DH: Effect of an inhibitor of noradrenaline uptake, desipramine, on cell proliferation in the intestinal crypt epithelium. Virchows Arch B Cell Pathol 1989;57:349-352.
27. Arimochi H, Morita K: Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006;541:17-23.
28. Fautz R, Husein B, Hechenberger C: Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat Res 1991;253:173-179.
29. Morita K, Ishimura K, Tsuruo Y, Wong DL: Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors. Brain Res 1999;816:309-316.
30. Morita K, Wong DL: Glucocorticoids enhance serum deprivation- but not calcium-induced cytotoxicity in rat C6 glioma cells. Cell Biol Int 2000;24:223-228.
31. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R: Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003;22:8271-8282.
32. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
33. Koubi D, Jiang H, Zhang L, Tang W, Kuo J, Rodriguez AI, Hunter TJ, Seidman MD, Corcoran GB, Levine RA: Role of Bcl-2 family of proteins in mediating apoptotic death of PC12 cells exposed to oxygen and glucose deprivation. Neurochem Int 2005;46:73-81.
34. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P: Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003;4:387-393.
35. Jaattela M, Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol 2003;4:416-423.
36. Panka DJ, Wang W, Atkins MB, Mier JW: The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006;66:1611-1619.
37. Thon L, Mohlig H, Mathieu S, Lange A, Bulanova E, Winoto-Morbach S, Schutze S, Bulfone-Paus S, Adam D: Ceramide mediates caspase-independent programmed cell death. FASEB J 2005;19:1945-1956.
38. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ, Lotan R: Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995;55:2191-2199.
39. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, Jansen B: A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 2000;6:693-704.
40. Schroy PC 3rd, Brown-Shimer S, Kim K, Johnson KA, Murnane MJ, Yang S, O'Brien MJ, Carney WP, Kupchik HZ: Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 1995;76:201-209.
41. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-232.
42. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175.
43. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D: MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006;25:20-31.
44. Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, Huet G, Lesuffleur T: Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 2004;96:145-151.
45. Yin L, Huang L, Kufe D: MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004;279:45721-45727.